The Centers for Disease Control and Prevention has announced a “new” influenza vaccine that is expected to go into clinical use within months.
The National Institute of Allergy and Infectious Diseases (NIAID) said in a statement Thursday that it will begin rolling out the new influenza vaccine to the public in late 2019.
The vaccine is a mixture of a virus that can be made from the respiratory virus and a virus made by a bacterium.
The vaccine will be the first to contain the live attenuated vaccine, which is designed to make people immune to the strain of flu that is being blamed for an outbreak in China that has infected nearly 1.1 million people.NIAIDs director Dr. Anthony Fauci said in an interview with Bloomberg Television that the vaccine will contain a strain of the influenza virus that is similar to the circulating strains in China.
The virus can be spread by a person who has been exposed to a recently vaccinated person or infected person, Faucy said.
“The reason for this is that it’s a strain that is quite similar to circulating strains,” he said.
The new vaccine is not a live attenuation vaccine.
Instead, it contains a combination of two viruses.
Fauci called the vaccine a “very, very important milestone.”
“I think it’s going to have an enormous impact,” he added.
The NIAID said the vaccine is designed specifically for people who have not been vaccinated with a live-attenuated vaccine.
The new vaccine will not be able to treat the people who already have influenza.